We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2914:TSEJapan Tobacco Inc. Analysis

Data as of 2026-03-10 - not real-time

¥5,743.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Japan Tobacco posted record FY2025 results, with operating margins near 25% and an adjusted operating profit surge of almost 25% YoY, underscoring strong pricing power and successful rollout of reduced‑risk products. Revenue is flat year‑over‑year, but profit expansion and a solid free cash flow generation of over ¥180 bn support the current dividend payout of roughly 4.3%. The stock trades at a PE around 20x and a PB close to 2.5x, while the beta is exceptionally low (well below 0.2), indicating limited price volatility relative to the market. Technical indicators show a bullish overall trend but a bearish MACD and price below the 20‑day SMA suggest short‑term pressure, with the current price sitting comfortably above the identified support of ¥5,551. The upside estimate of about 6½% and a “Extreme Greed” sentiment on the fear‑greed index add a modest bullish bias. However, the company carries a high debt‑to‑equity ratio (~46) and operates in a heavily regulated tobacco sector, which tempers the upside.
Given the attractive dividend yield, solid cash generation, and defensive positioning, the stock appears fairly valued with a slight upside potential. The combination of stable earnings, dividend sustainability, and modest growth from new product lines supports a buy stance for medium‑ to long‑term horizons, while short‑term investors may prefer to wait for price stabilization.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages
  • Bearish MACD histogram
  • Stable volume with limited upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Record profit growth and strong operating margins
  • Attractive dividend yield with sustainable payout
  • Technical bullish trend despite short‑term pullback

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Defensive consumer‑staples sector with low beta
  • Growth potential from reduced‑risk and pharmaceutical segments
  • Consistent cash flow supporting dividend and debt servicing

Key Metrics & Analysis

Financial Health

Profit Margin14.71%
P/E Ratio20.4
ROE12.15%
ROA6.39%
Debt/Equity45.79
P/B Ratio2.5
Op. Cash Flow¥514.1B
Free Cash Flow¥181.6B

Technical Analysis

TrendBullish
RSI44.5
Support¥5,551.00
Resistance¥6,182.00
MA 20¥5,921.40
MA 50¥5,805.26
MA 200¥5,086.80
MACDBearish
VolumeStable
Fear & Greed Index79.57

Valuation

Fair Value¥931.31
Target Price¥6,115.00
Upside/Downside6.48%
GradeFair
TypeBlend
Dividend Yield4.28%

Risk Assessment

Beta0.06
Volatility22.25%
Sector RiskLow
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.